Loading company…
SciFluor develops small molecule drug candidates for ophthalmology, fibrosis, and neurological conditions.
SciFluor develops small molecule therapeutics for ophthalmology, fibrosis, and neurological conditions using fluorine-based medicinal chemistry. Its lead candidate, SF0166, is designed for retinal diseases including Diabetic Macular Edema and wet Age-related Macular Degeneration. Founded in 2011 and based in Boston, US, the company raised USD 30.00 mn in April 2015 from Allied Minds, Invesco, and Woodford Patient Capital Trust.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in